STOCKS TELEGRAPH

Tag: Auris Medical Stock

  • Auris Medical Holding Ltd. (EARS) stock is Popping high today: What’s Going on?

    Auris Medical Holding Ltd. (EARS) stock is Popping high today: What’s Going on?

    Auris Medical Holding Ltd. (EARS) stock announced positive results of its in vivo study of OligoPhoreTM technology in adults after which the EARS stock price saw an uptrend of 9.04% to reach $3.62 a share at the time of this writing. It seems that momentum was already built in the previous session as EARS went up by 0.61% at closing. Let’s deeply discuss the EARS stock.

    OligoPhoreTM siRNA Study:

    Investors are responding positively to the announcement by EARS stock on June 21, 2021, according to which EARS’ OligoPhoreTM siRNA targeting the NF-κBinAdult T-cell Leukemia Lymphoma (ATLL) has significantly refrained the tumor growth. The research groups jointly conducted the study at the University of South Florida, Tampa FL, and the Washington University, St. Louis MO. The RNA nanoparticles were developed and evaluated by researchers of the study. In this process, two NF-κB signaling pathways were targeted by siRNA and peptide carrier of Auris’s OligoPhoreTM. The research groups administered siRNA nanoparticles to two mice groups with either tumor cell transplantation or ATLL tumor growth.

    Study Results:

    The study showed positive results as siRNA delivered rapidly to the tumor and target mRNA and protein expression had been significantly reduced which resulted the inhibit tumor growth. Tumor size, spleen size and peripheral blood lymphocyte counts were reduced significantly in the mice participated in the study as compared to control and the most aggressive tumors showed nearly zero growth.

    Acquisition of Trasir Therapeutics, Inc:

    On June 03, 2021, Auris stock entered the field of RNA therapeutics via the acquisition of Trasir Therapeutics, Inc , which is a private company in Tampa, FL famous for extrahepatic oligonucleotide delivery. The purchase price for this acquisition was $0.77 million common shares of EARS stock. The transaction was closed on June 1, 2021. The Trasir’s founder, Dr. Samuel Wickline joined the EARS’ leadership team by taking the role of Chief Scientific Officer.

    Repositioning of EARS stock:

    The Auris Medical initiated its repositioning via the acquisition of Trasir Therapeutics and aims to develop RNA therapeutics in the future amid spinning off existing assets in neurotology, rhinology, and allergology. EARS board of directors proposed a change in corporate name to Altamira Therapeutics Ltd in order to reflect the strategic repositioning. The shares will start to trade under the ticker symbol CYTO upon regulatory approvals.

    Conclusion:

    So far so good for Auris Medical stock as far as market sentiment is concerned due to the release of positive in vivo results of OligoPhoreTM siRNA Study by EARS stock. The management is focused in the repositioning of the company and planning to grow via the development of RNA therapeutics. In a nutshell, this stock can prove to be fruitful in the long run.

  • Auris Medical (EARS) Shares Quadruples on Positive Data of AM-301

    Auris Medical (EARS) Shares Quadruples on Positive Data of AM-301

    The Bermuda-based clinical-stage firm reports strong results from its drug-free nasal spray AM-301. The nasal spray results show potential for AM-301 to alleviatethe risk of Sars-CoV-2 virus.

    The last month of 2020 brings good news for the clinical-stage company, Auris Medical Holding Ltd. (EARS). The company reported that it has achieved positive efficacy data from clinical testing of AM-301 in vitro.

    The positive results of AM-301 have turned many investors towards the stock market to invest in EARS. Auris shares were trading at $1.11 in the previous trading session and investors saw great potential in $1 dollar stock to go big in long-term with potential nasal spray AM-301.

    EARS started the session at $1.46 as it continued to quadruple trading at $5.72. The shares have added +$4.61 surging up to 415.02% as of 11:57 A.M. EST. The trading volume is above 164 million compared to the average volume of 2.1 million.

    AM-301 is a drug-free nasal spray that was developed to prevent airborne pathogens and allergens. The company after testing AM-301 in vitro found out that it can be helpful in blocking Sars-CoV-2, the virus that causes COVID-19. The nasal spray forms a protective gel layer on the nasal mucosa that stops viruses to contact cells, saving from viral infections such as pathogens and allergens.

    AM-301 was tested for its potential to block the SARS-CoV-2 virus of nasal epithelial cells. These cells are sensitive to inhaled substances such as pathogens and allergens.

    Auris Medical’s affiliate Altamira Medica is developing the nasal spray AM-301.The efficacy data showed up to 99.4% reduction of viral titer in human epithelial cell culture.

    The company reported that daily treatment with AM-301 reflected healthy and efficient outcomes in protecting against viral infections. The average virus titers were 90% lower after 48 hours post-infection. Following 72- and 96-hours post-infection, the average virus titers reduced up to 99.2% and 99.4%.

    The company performed this testing in a four days period on reformed human nasal epithelia. The treatment was effective against Sars-CoV-2 in saline-treated control societies.

    The CEO and founder of Auris Medical, Thomas Meyer highlighted that their newly created spray formulationhas shown direct evidence for AM-301 to protect and limit the risk of nasal mucosal cell infection.

    Auris Medical Holding Ltd. (EARS)is looking forward to containing additional testing and apply for regulatory approval in the coming year.